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Cytidine triphosphate synthetase (CTPS) is the rate-limiting
enzyme in de novo CTP synthesis and is required for the forma-
tion of RNA, DNA, and phospholipids. This study determined
the kinetic properties of the individual human CTPS isozymes
(hCTPS1 and hCTPS2) and regulation through substrate con-
centration, oligomerization, and phosphorylation. Kinetic anal-
ysis demonstrated that both hCTPS1 and hCTPS2 were maxi-
mally active at physiological concentrations of ATP, GTP, and
glutamine, whereas the Km and IC50 values for the substrate
UTP and the product CTP, respectively, were close to their
physiological concentrations, indicating that the intracellular
concentrations of UTP and CTP may precisely regulate hCTPS
activity. Low serum treatment increased hCTPS2 phosphoryla-
tion, and five probable phosphorylation sites were identified in
the hCTPS2 C-terminal domain. Metabolic labeling of hCTPS2
with [32P]H3PO4 demonstrated that Ser568 and Ser571 were two
major phosphorylation sites, and additional studies demon-
strated that Ser568wasphosphorylatedby casein kinase 1both in
vitro and in vivo. Interestingly, mutation of Ser568 (S568A) but
not Ser571 significantly increased hCTPS2 activity, demonstrat-
ing that Ser568 is a major inhibitory phosphorylation site. The
S568A mutation had a greater effect on the glutamine than
ammonia-dependent activity, indicating that phosphorylation
of this site may influence the glutaminase domain of hCTPS2.
Deletion of the C-terminal regulatory domain of hCTPS1 also
greatly increased the Vmax of this enzyme. In summary, this is
the first study to characterize the kinetic properties of hCTPS1
and hCTPS2 and to identify Ser568 as a major site of CTPS2
regulation by phosphorylation.
Cytidine nucleotides are precursors for the synthesis of
nucleic acids and phospholipids (1–4) as well as the post-trans-
lational modification of proteins by sialylation (1–3) and the
regulation of enzymes such as CTP-phosphocholine cytidylyl-
transferase (2), carbamoyl phosphate synthetase, and phos-
phatidylserine synthase (5). CTP is the nucleotide with the
lowest cellular concentration (1, 6), making it rate-limiting
for RNA synthesis and other CTP-dependent events. Hence,
understanding the regulation of CTP synthesis is important for
many growth-related processes.
CTP synthetase (CTPS, EC 6.3.4.2)4 is the rate-limiting
enzyme for the synthesis of cytosine nucleotides from both the
de novo and uridine salvage pathways (7). CTPS consists of two
enzymatic domains. In the synthase domain, UTP is phosphor-
ylated by the -phosphoryl group of ATP to form 4-phospho-
UTP via an ATPase reaction (8–11). In the glutaminase do-
main, the substrate glutamine is hydrolyzed to glutamate and
NH3 (8), and the resultant NH3 is then transported to the syn-
thase domain active site through anNH3 tunnel (11, 12). NH3 is
then transferred to the phosphorylated UTP to form CTP (8).
GTP activates the reaction by accelerating the formation of a
covalent glutamyl-enzyme catalytic intermediate (8). CTPS has
three functionally distinct sites: the glutaminase site for gluta-
mine hydrolysis, the active site where CTP is formed, and the
allosteric site where GTP binds (13). CTPS is also regulated by
feedback inhibition, allowing the product CTP to inhibit the
activity of the enzyme (14–17).
There are two isoforms of CTPS in humans, CTPS1 and
CTPS2, and they share 74% amino acid identity (1, 7). Similarly,
there are two isoforms in yeast, URA7 and URA8; human
CTPS1 (hCTPS1) and hCTPS2 share just over 50% identity
with the yeast isoforms (7, 18, 19). Studies have shown that both
URA7 and hCTPS1 are regulated by phosphorylation, although
themechanisms are quite different. URA7 is phosphorylated by
cAMP-dependent protein kinase on Ser424 (3) and by protein
kinase C on Ser36, Ser330, Ser354, and Ser454 (20). This phosphor-
ylation increases enzyme activity and decreases the ability of
CTP to inhibit activity (3, 21–23). In addition, phosphorylation
only stimulates activity in the presence of subsaturating con-
centrations of ATP andUTP (22), and phosphorylation by both
kinases is less than additive compared with either kinase alone
(21).
In contrast to URA7, hCTPS1 is negatively regulated by
phosphorylation. Phosphorylation increases in the presence of
low serum compared with high serum, and hCTPS1 is phos-
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phorylated on Ser571, Ser574, and Ser575 (1). Significantly, the
C-terminal tail region that contains all the major phosphoryla-
tion sites on hCTPS1 is only found in higher eukaryotes and not
in yeast or Escherichia coli (1). Ser571 is phosphorylated by gly-
cogen synthase kinase-3 (GSK3), and Ser575 was shown to be
required for priming this phosphorylation (1). However, the
kinases responsible for the phosphorylation of Ser574 and Ser575
have not yet been identified. An increase in hCTPS1 phosphor-
ylation is paralleled by a decrease in CTPS activity, and this
decrease is reversed by the GSK3 inhibitor indirubin or by
dephosphorylation (1). Interestingly, the phosphorylation site
at Ser575 is not conserved in hCTPS2 (see Fig. 1), suggesting
that hCTPS1 and hCTPS2 may be regulated by different
kinases and/or signaling pathways. Other studies indicated
that hCTPS1 expressed in yeast cells can be phosphorylated by
protein kinase C on Ser462 andThr455 (24) and by cAMP-depen-
dent protein kinase (14). However, hCTPS1 was not phosphor-
ylated by cAMP-dependent protein kinase or protein kinase C
in HEK293 cells (1).
The oligomerization of CTPS also plays an important role in
the regulation of the enzyme. Studies with the yeast and E. coli
CTPS enzymes have shown that the active form of the enzyme
is a tetramer made up of two dimers, and the dimer form is
inactive (8). For both yeast and E. coli, CTPS exists as a dimer in
the absence of ATP and UTP, but in the presence of saturating
concentrations of ATP and UTP, CTPS exists as a tetramer (8,
25, 26). The crystal structure of the hCTPS1 synthase domain
shows that it is also a dimer of dimers with a synthase domain
very similar to that of E. coli (27). However, the influence of
ATP and UTP on tetramerization has not been determined for
either human isoform.
Although elegant analysis of the enzymatic properties of the
E. coli and yeast enzymes has been performed (4, 8, 12, 15, 16,
25, 28), the individual human isoforms have not been examined
in detail. The objective of this study was to explore the regula-
tion of hCTPS1 and hCTPS2 enzyme activity by substrates,
modulators, and phosphorylation as well as to determine the
requirement for ATP and/or UTP for enzyme tetramerization.
The results of this study identify optimal substrate concentra-
tions and determine that phosphorylation of sites within the C
terminus is likely to play a role in regulating the activity of these
enzymes.
EXPERIMENTAL PROCEDURES
hCTPS Plasmid Construction—The wild-type hCTPS1 con-
struct was made as described previously (1). Full-length cDNA
containing hCTPS2 (Image identification code 5268973) was
purchased from the American Type Culture Collection (Man-
assas, VA) (7). Full-length, wild-type hCTPS2 (WT-hCTPS2)
was amplified using the sense primer 5-AGCGTCGGATCCAT-
GAAGTACATCCTGGTCAC-3 (BamHI site is underlined)
and the antisense primer 5-AGCGTCCTGCAGTCACTTGT-
CGTCATCGTCTTTGTAATCGCTTATTTCCAACTCAG-
CTAT-3 (PstI site is underlined, FLAG sequence is italicized).
A FLAG sequence (DYKDDDDK) was introduced at the C ter-
minus of hCTPS2. The products of the PCR (WT-hCTPS2) and
the pcDNA4/myc-HisB vector (Invitrogen) were double-di-
gested with BamHI and PstI (New England Biolabs, Ipswich,
MA) and then purified from an agarose gel using a gel purifica-
tion kit according to the manufacturer’s instructions (Qiagen).
The vector and WT-hCTPS2 were ligated together using T4
DNA ligase (New England Biolabs). The complete WT-
hCTPS2 clone was then transformed into competent DH5
cells (Invitrogen) and plated on LB-agar containing 100 g/ml
ampicillin and grown overnight. Selected colonies were grown
overnight, and the WT-hCTPS2 DNA was isolated ac-
cording to the mini-prep protocol (Invitrogen). The WT-
CTPS2 clone was sequenced using the T7 sense primer for
the N terminus, the bovine growth hormone antisense
primer for the C terminus, and the sense primer 5-AGGC-
GAAAAGAGAGAATTTC-3 for the middle. All three
sequences confirmed the expected WT-hCTPS2 sequence
with a FLAG sequence at the C-terminal end.
Mutation of Phosphorylation Sites—The hCTPS1 point mu-
tations were constructed as described previously (1). Using the
WT-hCTPS1 construct, the 613 base pairs before the deleted
sequence were amplified using the forward primer 5-CACG-
AAGCTTGGCAGAAGC-3 and the reverse primer 5-GACT-
CGAGCGCTTGTCGTCATCGTCTTTGTAATCGAGCCTG-
CAGCCTTTCTG-3 (XhoI site is underlined, FLAG sequence
is italicized). This primer pair causes a deletion of amino acid
residues Ser562–Asp591. TheWT-hCTPS1 vector and the prod-
uct of the PCR were then digested with HindIII and XhoI
and purified. This digestion produced three fragments: the
pcDNA4 vector, the multiple cloning site region and the first
1137 base pairs of hCTPS1, and the PCR product containing
613 base pairs of hCTPS1 stopping at Leu561 and the FLAG
sequence. These three fragments were ligated together using
T4 DNA ligase, and the C-hCTPS1 clone was then trans-
formed into competent DH5 cells and selected as above.
The WT-hCTPS2-FLAG construct was used to make muta-
tions at five putative phosphorylation sites identified by mass
spectrometry: Ser564, Tyr567, Ser568, Ser571, and Ser574. The for-
ward and reverse primers used to make these mutations are
listed in supplemental Table S1. Mutations were made accord-
ing to the protocol in the QuikChange site-directedmutagen-
esis kit (Stratagene, La Jolla, CA) with slight modifications.
PCRs contained 20 ng of DNA. XL10-Gold supercompetent
cells (Stratagene) were used for transformation. Transformed
cells were incubated in Terrific Broth (12 g/liter tryptone, 24
g/liter yeast extract, 0.4% glycerol, 0.17 M KH2PO4, and 0.72 M
K2HPO4) for 2 h before plating on LB-agar containing 100 g/ml
ampicillin. The colonies were selected and grown overnight in
Terrific Broth containing 100 g/ml ampicillin, and DNA was
purified as above. DNA was sequenced using the bovine growth
hormone antisense primer to confirm correct mutations.
Cell Culture—HEK293 cells purchased from the University
of North Carolina Tissue Culture Facility were grown in high
glucose DMEM supplemented with 10% FBS and 1% penicillin/
streptomycin in a humidified 5% CO2 incubator at 37 °C.
Establishment of hCTPS Stable Cell Lines—HEK293 cells
were plated in 100-mm dishes and transfected using 45 g of
Lipofectamine (Invitrogen) and 9 g of DNA for the desired
hCTPS construct in DMEMwith no additives. On the day after
transfection, new DMEM containing 10% FBS and 1% penicil-
lin/streptomycin was added to the cells. The cells expressing
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the transfected hCTPS construct were selected over 4–6weeks
using 100 g/ml Zeocin (Invitrogen) as a selection agent. Once
selected, hCTPS protein expression was observed to be stable
for at least 4 days in the absence of Zeocin (data not shown).
Immunoprecipitation of hCTPS—Stable HEK293 cells ex-
pressing hCTPS constructs were plated in 100-mm dishes and
grown to confluency. The cells were washed twice with cold
PBS and lysed with 0.35 ml of radioimmune precipitation
assay (RIPA) buffer (150 mM NaCl, 9.1 mM Na2HPO4, 1.7 mM
NaH2PO4, 1% Nonidet P-40 substitute, and 0.5% sodium
deoxycholate) containing 1 g/ml leupeptin, 10 nM microcys-
tin, 1 mM Na3VO4, and 250 M phenylmethylsulfonyl fluoride.
The lysates were centrifuged, and the Coommassie protein
assay (Pierce) was performed on the supernatants. The lysates
were then aliquoted as desired and rotated with 10 l of anti-
FLAG beads overnight at 4 °C.
CTPSActivity Assay—hCTPS activity assayswere performed
as described previously (3, 21, 22). The amount of total pro-
tein needed for equal CTPS content after immunoprecipita-
tion was determined by Western blotting (supplemental Fig.
S1). Following immunoprecipitation of 5 mg of total protein
from cells expressing WT-CTPS1, 12 mg of total protein from
C-CTPS1 cells, or 1 mg of total protein from HEK293 cells
expressing the desired hCTPS2 construct, the lysates were
washed three times with RIPA buffer containing 5 g/ml leu-
peptin and once with 1CTPS reaction buffer (50mMTricine,
pH 8.1, 20 mM MgCl2, and 5 mM KCl). Unless otherwise speci-
fied, assay substrates were added to final concentrations of 1
mMATP, 0.1mMUTP, 0.1mMGTP, 1mM glutamine, and 18.75
nCi of [14C]UTP (Moravek Biochemicals, Brea, CA) in a final
volume of 50 l of 1 CTPS reaction buffer, pH 8.1. The sam-
ples were incubated for 1 h (CTPS1) or 15min (CTPS2) at 37 °C
with shaking. Ammonia-dependent CTPS activity was deter-
mined as described above except 10mM ammonium sulfate was
substituted for 10 mM glutamine. The reaction was stopped
by removing the tubes to ice and adding 10 l of 200 mM
EDTA. The samples were completely dried using a SpeedVac
(ThermoScientific, Waltham, MA), the dried pellets were
resuspended in 10 l of ddH2O, and 4 l of each sample were
spotted onto dry polyethylimine cellulose plastic-backed plates
(Selecto Scientific) that were prewashed for at least 10minwith
ddH2O, 5 min with 0.65 N HCl, and 1 min with methanol. The
nucleotides were separated using 0.65 N HCl as the ascending
chromatography buffer. The areas corresponding to 14C-la-
beled UTP and CTP were visualized by exposing the plate to a
phosphorimaging screen overnight. The screen was scanned
using a STORM or Typhoon imaging system (GE Healthcare).
Gel Filtration—HEK293 cells expressing WT-hCTPS2 were
lysed as above. The supernatants were filtered through 0.22-
m cellulose acetate spin filters (Agilent Technologies, Wilm-
ington, DE), and 200 l of sample was loaded onto a UPC-900
ÄKTA FPLC (Amersham Biosciences) and separated using a
Superose 12 column (Amersham Biosciences) at 0.2 ml/min
using a low salt buffer (50 mM Tris, pH 8.0, 50 mM NaCl, 1 mM
dithiothreitol, 0.1 mM EDTA, 10 mM MgCl2) in the absence or
presence of 1 mM ATP and/or 1 mM UTP. The fractions were
collected in 0.5-ml aliquots. Gel filtration standards (Bio-Rad)
were also separated using buffer without nucleotides (supple-
mental Fig. S2). Fractions 15–29 were then analyzed for endog-
enous CTPS1 or hCTPS2-FLAG expression using Western
blotting as described below.
Immunoblotting—Cell lysates from immunoprecipitations
were washed three times with RIPA buffer containing 5 g/ml
leupeptin and resuspended in 50 l of Laemmli buffer (final
concentrations: 0.25 M Tris, pH 6.8, 2% SDS, 10% glycerol, 5%
-mercaptoethanol, 0.001 g/ml bromphenol blue). Gel filtra-
tion fractions 15–29 (25 l) were diluted in 25 l of Laemmli
buffer. All of the samples were boiled for 5 min before loading
them onto a 10% SDS-PAGE gel. The proteins were separated
at 120 V and transferred to polyvinylidene fluoride Immo-
bilon-FLmembrane (Millipore, Billerica,MA) for 60–90min at
400mA at 4 °C. Themembranes were blocked for 1 h with a 1:1
mixture of Odyssey blocking buffer (LiCor, Lincoln, NE) and
PBS. The membranes were incubated with a mouse anti-FLAG
antibody (Sigma-Aldrich) and a rabbit anti-CTPS1 antibody,
washed with Tris-buffered saline with Tween 20 (10 mM Tris,
150 mM NaCl, 0.05% Tween 20, pH 8.0), incubated with IRDye
680 goat anti-mouse and IRDye 800CW goat anti-rabbit anti-
bodies (LiCor), andwashed againwithTris-buffered salinewith
Tween 20. The proteins were detected using an Odyssey infra-
red imaging system (LiCor).
In Vivo Labeling with [32P]Orthophosphate—HEK293 cells
expressing hCTPS constructs were treated with 10 or 0.1% FBS
overnight. The next day, the medium was replaced with phos-
phate-free DMEM with 10 or 0.1% FBS and 0.1 mCi/ml
[32P]H3PO4 (MP Biomedicals, Irvine, CA) (0.5 mCi total) for
4 h. The cells were thenwashedwith PBS and lysed as described
above. Cell lysate from one 100-mm dish was incubated with
10 l of FLAG antibody conjugated to agarose beads (Sigma-
Aldrich) overnight at 4 °C. FLAGbeadswerewashed twicewith
RIPA buffer, resuspended with 50 l of Laemmli buffer, and
boiled 5 min. Immunoblotting was performed as described
above. After scanning on an Odyssey infrared imaging system
to detect either hCTPS1-FLAG or hCTPS2-FLAG, the mem-
brane was dried thoroughly and exposed to a phosphorimaging
screen (GE Healthcare) overnight to detect phosphorylated
hCTPS1 and hCTPS2. The screen was scanned on the STORM
imaging system.
Phosphorylation of hCTPS with CK1—HEK293 cells express-
ing WT-hCTPS2 or hCTPS2-S568A were lysed and immuno-
precipitated with FLAG antibody beads as above. FLAG beads
were washed twice with RIPA buffer, and the hCTPS proteins
were eluted with 1.0 mg/ml FLAG peptide in 10 mM Tris, pH
7.5, plus 100mMNaCl.WT-hCTPS2 and hCTPS2-S568Awere
incubatedwith purified casein kinase 1 (CK1) (CellSignal, NEB)
with 50M [32P]ATP (12.5Ci total) in 100mMTris, pH 7.5, 10
mM MgCl2, 50 mM -glycerol phosphate, 1.0 mM sodium
orthovanadate, 1.0 mM dithiothreitol, and 0.5 mM EGTA for 60
min at 30 °C. The reaction was terminated with SDS-PAGE
sample buffer, and the sample was applied to SDS-PAGE,
stained with Coomassie, and destained. The dried gel was then
exposed to film.
Phosphorylation Site Identification by Mass Spectrometry—
Cell lysates from HEK293 cells expressing WT-hCTPS2 that
were treated with 10 or 0.1% FBSwere separated by SDS-PAGE
and transferred to nitrocellulose (Osmonics, Westborough,
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MA) for 60 min at 400 mA. The proteins were visualized with
MemCode (Pierce). The bands corresponding to WT-hCTPS2
were excised and cut into1-mmpieces before destainingwith
MemCode Eraser. The pieces were incubated 1 h at 37 °C with
1% polyvinylpyrrolidone in 100 mM glacial acetic acid. The
membrane pieceswere thenwashedwith ddH2Oand incubated
with 0.5 g of trypsin in ammonium bicarbonate overnight at
37 °C. Trypsin was removed to a new tube, the membrane
pieces were washed three times with ddH2O, and the ddH2O
was added to the trypsin. The samples were dried in a SpeedVac
and resuspended in 10 l of ddH2O.
The sampleswere then analyzed by online LC-MS/MSusing an
Eksigent NanoLC system (Dublin, CA) coupled to a Thermo
Fisher Scientific LTQ-Orbitrap XL (Waltham, MA) mass spec-
trometer. Five microliters of the sample was injected onto a New
Objectives IntegraFritC18 trap column (Woburn,MA).The tryp-
tic peptides were eluted by reverse phase HPLC from a 10-cm 
75-m inner diameter  360-m outer diameter PepMap capil-
lary C18 column (Dionex, Sunnyvale, CA). A gradient of 5–45%
BufferB in50minwasused for theelutionwith0.1% formicacidas
Buffer A and 95% acetonitrile, 0.1% formic acid (Thermo Fisher
Scientific) as Buffer B. The eluent was delivered to the mass spec-
trometer’s source by nano-electrospray using a New Objective
PicoViewESI source. The spectral datawere acquired throughout
the elution as cycles of one Fourier transformmass spectrometry
(30,000 resolution) and five subsequent data-dependent ion trap
mass-spectrometry/mass spectrometry.
The mass spectra were searched against a custom data-
base containing only hCTPS2 (GenBankTM accession number
CAI40086.1). First, the raw mass spectral data were processed
by BioWorks Browser v.3.3.1 software (Thermo Fisher Scien-
tific). The resulting centroid peak list was searched against the
custom database using an in-house version of the Mascot
search engine (Matrix Science, Boston, MA). The criteria for
the search are as follows: tryptic cleavage with two potential
missed cleavages, peptide mass tolerance  0.5 Da, fragment
mass tolerance  1 Da, and variable modifications: oxidized
methionine and S,T,Y phosphorylation.
Data Analysis—All of the data are expressed as the means 
S.E. hCTPS activity assays were quantified using ImageQuant
5.0 (GEHealthcare).Western blotswere quantifiedOdyssey 2.1
software (LiCor). The data were analyzed using GraphPad
Prism 4.0 (GraphPad Software, San Diego, CA).
RESULTS
Dependence of hCTPSActivity on pHandTime—The influence
of the assay conditions on the activity of the individual human
CTPS isozymes was compared. HEK293 cells expressing hCTPS1
or hCTPS2 were lysed and isolated by immunoprecipitation with
anti-FLAG antibody. Using 5 mg (hCTPS1) or 1 mg (hCTPS2) of
cell lysate resulted in the purification of similar amounts of
hCTPS1 and hCTPS2 as determined by anti-FLAG immunoblot.
Substrates were added to final concentrations of 1 mM ATP, 0.1
mM UTP, 0.1 mM GTP, 1 mM glutamine, and 18.75 nCi of
[14C]UTP (6.8M), basedon theoptimal assay conditions (pH8.1)
determined earlier for hCTPS1 (1).When assayed in the presence
of saturatingconcentrationsofATP,GTP,andglutamineandsub-
saturating concentrations of UTP, hCTPS1 demonstrated an ini-
tial rate value of 36  4 pmol/min, with the reaction rate
remaining linear up to 60 min. Under the same conditions,
hCTPS2 demonstrated faster initial rate kinetics at 98  2
pmol/min andwas linear only to 15min. Based on the results of
these studies, subsequent assays were performed for 1 h
(CTPS1) or 15 min (CTPS2). Varying the reaction pH demon-
strated that neutral to slightly basic conditionswere optimal for
both hCTPS1 and hCTPS2 (supplemental Fig. S1).
Dependence of hCTPS Activity on ATP, UTP, and Glutamine
Concentrations—CTPS utilizes ATP, UTP, and glutamine to
synthesize CTP (29). Assays were performed to determine the
individual kinetic parameters for these substrates. hCTPS1 or
hCTPS2 protein was isolated and incubated with various con-
centrations of ATP, UTP, or glutamine at pH 8.1 for 1 h
(hCTPS1) or 15min (hCTPS2) as described above (Fig. 1,A–C).
hCTPS1 displayed the following kinetic parameters. Km val-
ues of 170  110, 590  240, and 27  9 M were determined
for ATP, UTP, and glutamine, respectively. In comparison,
hCTPS2 displayed Km values for ATP, UTP, and glutamine of
60  20, 190  80, and 100  40 M, respectively. Increasing
the UTP concentration such that it was no longer limiting
resulted inVmax values of 390  50 and 340  40 pmol/min for
hCTPS1 and hCTPS2, respectively (Fig. 1 and Table 1). Incuba-
tion with higher concentrations of ATP (10 mM) inhibited the
activity of both hCTPS1 and hCTPS2 (data not shown).
Modulation of hCTPS Activity by GTP and CTP—Previous
studies have shown that GTP increases the rate of formation of
the glutamyl-enzyme intermediate (16, 21, 30–32), whereas
CTP acts as a feedback inhibitor (14–16). Therefore, we com-
pared the effects of GTP and CTP concentrations on hCTPS1
and hCTPS2 activity. hCTPS1 or hCTPS2 were incubated with
various concentrations of GTP (Fig. 1D) or CTP (Fig. 1E). GTP
stimulated CTPS activity with Ka values of 1.6  0.6 and 8  3
M for WT-hCTPS1 and WT-hCTPS2, respectively (Table 1).
Higher concentrations of GTP (10 mM) also inhibited WT-
hCTPS1 and WT-hCTPS2 activity (data not shown). Under
these assay conditions, GTP was required for hCTPS1 and
hCTPS2 activity, because only minimal CTP synthesis was
observed in the absence of GTP (Fig. 1D). In contrast to the
effects of the other nucleotides, CTP inhibited WT-hCTPS1
and WT-hCTPS2 activity with IC50 values of 42  8 and 40 
10 M, respectively, demonstrating similar CTP feedback inhi-
bition of these enzymes (Fig. 1E).
Requirement of Nucleotides for hCTPS Tetramerization—
Previous studies have shown that CTPS is regulated by tet-
ramerization. CTPS can form a dimer of dimers, and the for-
mation of tetramers by ATP and/or UTP activates the enzyme
(8, 11, 27, 29). HEK293 cells expressing WT-hCTPS2 were
lysed, and the proteins were separated by size exclusion chro-
matography on a calibrated Superose 12 column in the absence
or presence of 1 mM ATP and/or 1 mM UTP plus MgCl2. Based
on the elution of protein molecular weight standards and the
calculated molecular weight of hCTPS1 and hCTPS2 (7),
monomers elute in fraction 24 or higher, dimers elute in frac-
tions 22 and 23, and tetramers elute in fractions 21 or lower.
Total protein eluted between fractions 15 and 40 (supplemental
Fig. S2). Fractions 15–29 were analyzed for the presence of
hCTPS1 and FLAG-tagged hCTPS2 using a CTPS1 antibody to
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detect endogenous CTPS1 and a FLAG antibody to detect
CTPS2-FLAG. In the absence of ATP and UTP, hCTPS1 was
found in fractions 22–28 and hCTPS2 was found in fractions
21–25, corresponding to both isoforms being present primarily
as monomers and dimers (supplemental Fig. S2, D and E, blue
line). In contrast, in the presence of ATP and/or UTP, hCTPS1
was detected in fractions 16–26 and hCTPS2 was detected in
fractions 20–23 (supplemental Fig. S2, D and E, red (ATP),
green (UTP), and black (ATP/UTP) lines). These data indicated
that in the presence of these nucleotides, hCTPS1 was detected
as monomers, dimers, and tetramers, whereas hCTPS2 was
present primarily as dimers and tetramers.
Regulation of hCTPS by Phosphorylation—Human CTPS1 is
negatively regulated by reversible phosphorylation on multiple
serines in the C terminus of the enzyme. Under low serum
conditions (LS, 0.1% FBS), WT-hCTPS1 is phosphorylated by
GSK-3, which is correlated with a decrease in enzyme activity
(1). Because hCTPS2 lacks an important phosphorylation site
identified in hCTPS1 (Ser575; Fig. 2A), experiments were
performed to compare hCTPS2 and hCTPS1 phosphoryla-
tion under these conditions. HEK293
cells expressing hCTPS1 or hCTPS2
were metabolically labeled with 100
Ci/ml [32P]H3PO4. Similar to
hCTPS1 (Fig. 2B, first two lanes) (1),
hCTPS2 was phosphorylated 2-
fold greater in the presence of LS
than in the presence of high se-
rum (HS, 10% FBS) (Fig. 2C, first
two lanes). hCTPS2 was also iso-
lated from unlabeled HEK293 cells
treated with either HS or LS and
trypsin-digested, and the peptides
were analyzed for phosphorylation
sites by LTQ-OrbiTrap mass spec-
trometry as described under “Ex-
perimental Procedures.”
In the presence of LS, three single
phosphorylation eventswere identi-
fied on Ser564, Ser571, and Ser574, all
sites located in the C terminus of
hCTPS2 (Table 2 and supplemental
Fig. S4, A–C). A double phosphory-
lation event was also detected con-
taining phosphorylated Ser568 and
Ser571 (Table 2 and supplemental
Fig. S4D). In the presence of HS, the
profile was slightly different, with
single phosphorylation events de-
tected on Tyr567, Ser568, and Ser571
and a double phosphorylation event
at Ser568 and Ser571 (Table 2 and
supplemental Fig. S4, E–G). Three
of these sites, Ser568, Ser571, and
Ser574, have been confirmed as
phosphorylation sites in large scale
phosphopeptide analyses of cell
lysates (33, 34). No additional phos-
FIGURE 1. Influence of substrates and allosteric effectors on hCTPS1 and hCTPS2 activity. HEK293 cells
expressing hCTPS1-FLAG (solid squares, solid line, black bar) and hCTPS2-FLAG (open triangles, dotted line, gray
bar) were lysed, immunoprecipitated with FLAG antibody conjugated to agarose beads, and assayed for CTPS
activity. The samples were incubated with the indicated ATP (A), UTP (B), or glutamine (C) concentrations for 1 h
(CTPS1) or 15 min (CTPS2) at 37 °C. Alternatively, the samples were incubated with the indicated effectors GTP
(D) or CTP (E) concentrations for 1 h (CTPS1) or 15 min (CTPS2) at 37 °C. All of the data are expressed as
pmol/min CTP formed and are from three (CTPS1) or four (CTPS2) experiments.
TABLE 1
Kinetic parameters of hCTPS1 and hCTPS2 activation
ND, not determined.
WT-CTPS1 C-CTPS1 WT-CTPS2 CTPS2-S568A CTPS2-S571A
ATP (Km) 170  110 M ND 60  20 M ND ND
UTP (Km) 590  240 M 1900  900 M 190  80 M 420  60 M 800  200 M
UTP (Vmax) 390  50 pmol/min 1100-  200 pmol/min 340  40 pmol/min 970  40 pmol/min 490  50 pmol/min
Gln (Km) 27  9 M ND 100  40 M 72  13 M ND
GTP (Ka) 1.6  0.6 M ND 8  3 M ND ND
CTP (IC50) 42  8 M 57  9 M 40-  10 M 72  7 M 45  6 M
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phorylation sites were detected in hCTPS2, and the sequence
coverage is shown in supplemental Fig. S5. Based on these
observations and our previous studies in hCTPS1 (1), we desig-
nated this region as the C-terminal regulatory domain (CRD).
To examine the importance of these phosphorylation
sites, single point mutations at Ser571, Ser574, and Ser575 as
well as a deletion of the CRD starting at residue Ser562 (C-
CTPS1) were made for hCTPS1 (1) as well as single point
mutations at Ser564, Tyr567, Ser568, Ser571, and Ser574 in
hCTPS2. These mutant hCTPS proteins were stably expressed
in HEK293 cells. As determined by anti-FLAG immunoblot-
ting, WT-hCTPS1 and the hCTPS1 point mutations were
expressed at a similar level, whereas the C-CTPS1 was
expressed at a much lower level. In addition, WT-hCTPS2 and
the hCTPS2 point mutations were expressed at similar levels to
each other (Fig. 2 and supplemental Fig. S1). These cells were
labeled with [32P]H3PO4 and treated under HS or LS condi-
tions, and the incorporation of radioactivity into hCTPS1 and
hCTPS2 was determined by SDS-PAGE analysis.
Treatment of HEK293 cells with LS conditions increased
hCTPS phosphorylation compared with HS conditions (Fig.
2). Mutation of Ser574 (hCTPS1) or Ser564, Tyr567, or Ser574
(hCTPS2) did not significantly affect incorporation of 32P
into hCTPS1 or hCTPS2, respectively (Fig. 2, Ser564; data not
shown). However, the C-CTPS1 and CTPS1-S575A pro-
teins showed little to no phosphorylation compared with
WT-CTPS1, consistent with phosphorylation occurring in
the CRD (Fig. 2B, third, fourth, ninth, and tenth lanes).
CTPS1-S571I was phosphorylated less than WT-CTPS1 but
more than the C-CTPS1 and the CTPS1-S575A proteins
(Fig. 2B, fifth and sixth lanes). In addition, compared with
WT-CTPS2, the CTPS2-S568A and CTPS2-S571A proteins
displayed a significant reduction in 32P incorporation after
HS and LS treatment, suggesting that Ser568 and Ser571 are
the two major phosphorylation sites in hCTPS2 under these
conditions (Fig. 2C).
Sequence analysis of the CRD suggested the potential for
phosphorylation byCKI, a kinase that recognizes (pS/pT)XX(S/
T), where (pS/pT) is phosphoserine or phosphothreonine and
X refers to any amino acid (35, 36). To investigate the influence
of CKI on CTPS phosphorylation, the cells were metabolically
labeledwith 32P as described above and incubatedwith or with-
out the CKI inhibitor, IC261. As shown in Fig. 2D, incubation
with IC261 significantly inhibited the phosphorylation of WT-
hCTPS2 and reduced the phosphorylation of the S568A,
S571A, and S574A mutant CTPS2 proteins.
CK1 Phosphorylates hCTPS2 on Ser568—To further investi-
gate the role ofCKI to phosphorylate hCTPS2,we examined the
phosphorylation of immunoprecipitated WT and S568A pro-
teins. These proteins were isolated and phosphorylated with
purified CKI as described under “Experimental Procedures.”
Both WT CTPS2 and S568A proteins were phosphorylated by
CK1; however, hCTPS2-S568A incorporated 35–40% less
than WT-hCTPS2, demonstrating the importance of this site
(Fig. 3).
Effects of CRD Mutations on hCTPS Activity—Our previ-
ous data demonstrated that an increase in phosphorylation
correlated with a decrease in hCTPS1 activity (1). Therefore,
the enzymatic activities of several mutant enzymes, includ-
ing C-hCTPS1, CTPS2-S568A, and CTPS2-S571A, were
determined. Time course analyseswere performed to assess the
rate of CTP formation over time, and UTP dose-response
curves were performed to determine the Vmax for the mutated
enzymes. CTP dose-response curves were also performed to
determine whether phosphorylation of the CRD affected feed-
back inhibition by CTP.
As shown in Fig. 2B, the C-hCTPS1 construct showed neg-
ligible phosphorylation compared with WT-hCTPS1. The
kinetic properties of C-hCTPS1 were compared with WT-
hCTPS1. C-hCTPS1 had higher activity at every time point
FIGURE 2. Phosphorylation of hCTPS1/2 in serum-starved cells; involve-
ment of CK1. A, alignment of C-terminal regulatory domains of hCTPS1 and
hCTPS2. The amino acid sequences of hCTPS1 and hCTPS2 starting at residue
561 through the end of the enzyme are shown. Serine 575, which is uniquely
phosphorylated in hCTPS1, is underlined. Low (0.1%) serum conditions
increase hCTPS phosphorylation. B and C, HEK293 cells stably transfected
with hCTPS1-FLAG (B) or hCTPS2-FLAG (C) DNA were incubated overnight in
high (10%) or low (0.1%) FBS. D, HEK293 cells stably transfected with hCTPS2-
FLAG DNA were incubated overnight in low serum (0.1% FBS) in the absence
or presence of 50 M IC261, the CK1 inhibitor. The cells were then labeled with
100 Ci/ml [32P]H3PO4 in phosphate-free DMEM for 4 h. The lysates were
separated by SDS-PAGE, transferred to a PVDF membrane, and blotted with a
FLAG antibody to detect CTPS protein (bottom blot). The membranes were
then dried and exposed to a PhosphorImager screen overnight to detect
phosphorylated CTPS (top blot).
TABLE 2
Probable phosphorylation sites for human CTPS2 as determined by
mass-specific analysis on an Orbitrap LC-MS/MS
The sequence represents amino acids Leu561–Arg579 of human CTPS2. Detected
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compared withWT-hCTPS1, with initial rate kinetics of 100 
30pmol/min that reached equilibriumat 15minwhenUTPwas
limiting (supplemental Fig. S3). When UTP was not limiting,
the Vmax for C-hCTPS1 was 1100  200 pmol/min, which is
2.5 times higher than the Vmax for WT-hCTPS1. However,
the Km for UTP was also higher for C-hCTPS1 at 1.9  0.9
mM, compared with 0.59  0.24 mM for WT-hCTPS1. Despite
the difference in apparent affinity for UTP, the feedback inhi-
bition ofC-hCTPS1 byCTP (IC50 of 57 9M)was similar to
WT-CTPS1 (supplemental Fig. S3 and Table 1).
Because hCTPS2-S568A and hCTPS2-S571A showed the
greatest decrease in overall hCTPS2 phosphorylation (Fig. 2C),
we chose to perform a kinetic analysis of these enzymes. Inter-
estingly, CTPS2-S571A showed similar kinetics toWT-CTPS2
with respect to time, UTP, and CTP, with only a slight increase
in Vmax (490  50 pmol/min) and a decrease in UTP affinity
(800  200 M) (Fig. 4 and Table 1). However, the hCTPS2-
S568A enzyme showedmuch higher activity than the wild-type
enzyme, with initial rate kinetics of 178 4 pmol/min (Fig. 4A)
and a Vmax of 970  40 pmol/min (Fig. 4B). Despite this, the
affinity of hCTPS2-S568A was lower for both UTP and CTP,
with aKm of 420 60 M for UTP (Fig. 4B) and an IC50 of 72
7 M for CTP (Fig. 4C and Table 1). These data indicate that
Ser568 is a major regulatory phosphorylation site on hCTPS2
and that mutation of this site relieves the inhibitory effects of
phosphorylation.
Mutation of Ser568 Affects the Glutaminase Activity of
hCTPS2—Because we observed enhanced activity with the
S568A mutant, we hypothesized that phosphorylation of
this site may affect the glutaminase activity of hCTPS2. To
test this idea, we compared the activity of WT-hCTPS2
and hCTPS2-S568A when assayed with ammonia, the prod-
FIGURE 3. Phosphorylation of hCTPS2 with CK1; identification of Ser568 as
a phosphorylation site. HEK293 cells expressing WT-hCTPS2-FLAG or
hCTPS2-S568A-FLAG were lysed, and hCTPS2 proteins were isolated as
described above. hCTPS2 proteins were incubated with purified CK1 and
[32P]ATP as described under “Experimental Procedures,” and the phosphory-
lated proteins were applied to SDS-PAGE and exposed to film. Lanes 1 and 2,
no kinase; lanes 3 and 4, 500 units of CK1; lanes 5 and 6, 1000 units of CK1.
A, shown are the phosphorylated (32P) hCTPS2 (WT) and S568A mutant pro-
teins and the corresponding Coomassie-stained gel bands. B, the hCTPS2
bands were excised and quantitated by scintillation counting. This experi-
ment was repeated twice with similar results.
FIGURE 4. Effect of phosphorylation site mutations on hCTPS2 activity.
HEK293 cells expressing WT-hCTPS2-FLAG (solid squares, solid line), hCTPS2-
S568A-FLAG (open triangles, dashed line), or hCTPS2-S571A-FLAG (open cir-
cles, dotted line) were lysed and assayed for CTPS activity as described above.
A, samples were incubated for the indicated time intervals at 37 °C from 1 to
90 min. The data are expressed as nmol of CTP formed and are from three
separate experiments. Note that the y axis of A is expressed as nmol of CTP
synthesized, not pmol/min CTP as on the other graphs. B, samples were incu-
bated with the indicated UTP concentrations for 15 min at 37 °C. C, samples
were incubated with the indicated CTP concentrations for 15 min at 37 °C. The
data in B and C are expressed as pmol/min CTP formed and are from three
separate experiments. Note that the WT-hCTPS2 data are the same data as
presented in supplemental Fig. 1B and Fig. 1 (B and E) and are shown here for
comparison purposes.
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uct of the glutaminase reaction. WT-hCTPS2 showed simi-
lar amounts of activity when assayed with either Gln or
ammonia as the substrate (Fig. 5). By comparison, hCTPS2-
S568A displayed approximately three times higher activity
thanWT-hCTPS2when assayedwithGln, similar to our earlier
results (Table 1). However, when assayed with ammonia,
hCTPS2-S568A had lower activity andwasmore similar toWT
hCTPS2 (Fig. 5). These data suggested that phosphorylation of
the CRD (Ser568) may influence the ability of hCTPS2 to utilize
Gln but not ammonia as a substrate. Kinetic analysis demon-
strated that the Km for Gln was essentially unchanged for this
mutant (Table 1). Instead, these results are consistent with the
S568A mutation, affecting the rate of glutamine hydrolysis
(Table 1).
DISCUSSION
The studies described here are the first to examine the
detailed kinetic properties of the individual hCTPS1 and
hCTPS2 enzymes and to investigate the regulation of hCTPS2
by phosphorylation. Specifically we observed important differ-
ences in the kinetic behavior and phosphorylation of these
enzymes. hCTPS1 and hCTPS2 activity was maximal when
assayed with the approximate physiological concentrations for
ATP (3.2mM), GTP (0.5mM) (6), and glutamine (0.65mM) (37);
however, hCTPS2 exhibited significantly faster initial rate
kinetics than hCTPS1. In contrast to earlier studies withGSK-3
and hCTPS1, we find that hCTPS2 was phosphorylated by
CK1 and identified Ser568 as an important site of phosphoryla-
tion and regulation. Importantly, these studies suggest that the
multisite phosphorylation of the CRD of both hCTPS1 and
hCTPS2 may occur through regulation of the glutaminase
activity of these enzymes.
As expected, we observed thatGTPwas required for hCTPS1
and hCTPS2 activity. This is similar to that observed with the
E. coli enzyme (28) but differs from that observedwith the yeast
CTPS enzymes (URA7,8), in which GTP enhances CTPS activ-
ity but is not absolutely required (4). At high GTP concentra-
tions, significant inhibition of CTP synthesis was observed but
not until GTP concentrations were well above normal levels.
This property is also distinct from the E. coli enzyme, in which
higher concentrations ofGTP (0.15mM) inhibit CTP formation
through an uncoupling of Gln hydrolysis and CTP synthesis
(31).
These results indicate that the maximal enzymatic rates of
hCTPS1 and hCTPS2 occur at physiological concentrations
of ATP, GTP, and glutamine. By contrast, the physiological
concentrations of UTP and CTP are close to their Km and
IC50 values, respectively, and may thereby facilitate a greater
control over CTPS activity. The Km value for UTP for
hCTPS1 activity is 590  240 M, close to the cellular con-
centration of 600 M. This may allow small changes in UTP
levels to control CTP synthesis. We observed that the Km
value for UTP for hCTPS2 is much lower at 190  80 M,
potentially explaining the faster initial rate kinetics displayed by
hCTPS2 compared with hCTPS1.
Both enzymes showed similar CTP feedback inhibition prop-
erties. The IC50 values were 42 8 and 40 10M for hCTPS1
and hCTPS2, respectively. These values are close to the lower
end of the physiological concentration of CTP (280  240 M),
suggesting that at normal CTP levels, hCTPS enzymes are not
very active. However, as CTP levels decline, hCTPS is likely to
become more active. The high affinity for CTP, particularly in
comparison with the affinity for UTP, may be instrumental in
determining the CTP concentrations within the cell, particu-
larly when CTP is in high demand.
Activity of both hCTPS1 and hCTPS2 was regulated by
oligomerization as seen with other CTPS enzymes (8, 16, 25,
38). Tetramerization can be induced by ATP and/or UTP,
and at high enzyme concentrations equilibrium often exists
between monomers, dimers, and tetramers (29). In the ab-
sence of ATP and UTP, hCTPS1 and hCTPS2 are found
primarily as monomers and dimers. However, in the pres-
ence of 1 mM ATP and/or UTP, hCTPS1 and hCTPS2 form
tetramers, suggesting that both hCTPS isoforms normally
exist as tetramers. It has been shown that CTPS is only active
in this tetrameric form (8, 11, 27, 29). In contrast, the yeast
CTPS (URA7) requires UTP but not ATP for tetrameriza-
tion, although ATP enhances tetramerization (8). Similar to
hCTPS, ATP or UTP alone can induce the formation of
tetramers in E. coli (25). However, in contrast to hCTPS,
ATP and UTP synergistically stimulate tetramer formation
in E. coli (16). Interestingly, the pattern of elution of hCTPS1
appears to be more complex than simple monomers, dimers,
and tetramers. In particular, the presence of hCTPS1 in
earlier fractions could indicate that hCTPS1 is part of a
larger signaling complex, although this has not been directly
investigated.
Importantly, these studies identified phosphorylation of
the C-terminal region of hCTPS as an additional and impor-
tant mechanism of regulation. This is predicted to be a
highly unstructured region and is unique to CTPS enzymes
from higher eukaryotes (1). Based on these and our previous
studies with CTPS1, we termed this region the CRD. We
observed the greatest increase in hCTPS phosphorylation
under nutrient deprivation conditions (represented here by
treating cells with 0.1% FBS). As previously shown, this
increase in phosphorylation correlates with a decrease in
hCTPS1 activity (1). This differs from other CTPS enzymes,
FIGURE 5. Comparison of glutamine and ammonia-dependent activity for
hCTPS2. HEK293 cells expressing WT-hCTPS2-FLAG and hCTPS2-S568A-
FLAG were lysed, and hCTPS2 was isolated by FLAG antibody immunoprecipi-
tation. hCTPS2 proteins were assayed for CTPS activity as described above
with 10 mM glutamine or 10 mM ammonia as the substrate. The data are
expressed as pmol/min CTP formed from two experiments. ***, p  0.001; **,
p  0.01 from the mean of duplicate samples.
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including yeast URA7 (which lacks the CRD), in which phos-
phorylation activates the enzyme (3, 21–23). In this study we
demonstrate that deletion of the CRD from hCTPS1 resulted
in enhanced activity, supporting the thesis that this region is
important to the regulation of hCTPS1.
Similar to hCTPS1, we determined that hCTPS2 con-
tains multiple phosphorylation sites in the C-terminal tail,
including Ser564, Tyr567, Ser568, Ser571, and Ser574. We iden-
tified Ser568 as an important site of hCTPS2 regulation,
because mutating this phosphorylation site significantly
increased hCTPS2 activity. Moreover, we show that Ser568 is
phosphorylated by CK1 in vitro and is a major phosphoryla-
tion site in vivo. Importantly, our studies suggest that the
effect of Ser568 phosphorylation may be to modulate the
glutaminase reaction. This is supported by our findings that
mutation of this site resulted in enhanced activity with Gln
but not ammonia as the substrate. Based on the reported
x-ray crystal structure for the glutaminase domain of
hCTPS2 (PDBe), we propose that the flexible CRD may
interact with the neighboring glutaminase domain when
phosphorylated. Mutation of Ser568 in hCTPS2 decreased
phosphorylation and feedback inhibition by CTP (Figs. 2C
and 4C), indicating that phosphorylation of Ser568 may also
contribute to regulation of hCTPS2 through this mecha-
nism. This contrasts that observed with the yeast enzymes
(URA7, 8), which show decreased CTP inhibition after phos-
phorylation of Ser424 (3, 22).
Comparison of the phosphorylation sites in hCTPS1 and
hCTPS2 shows that the proposed phosphorylation site for
GSK3 (Ser575) in hCTPS1 is not conserved in hCTPS2 (Fig.
1). This suggests that different kinases are responsible for the
phosphorylation of hCTPS2. Ser568, as well as other phos-
phorylation sites in the CRD of hCTPS2, is a consensus phos-
phorylation site for CK1, and our experiments indicate that
CK1 contributes to the phosphorylation of hCTPS2. Both the in
vivometabolic labeling studies using the CK1 inhibitor (IC261)
and the in vitro phosphorylation studies with active CK1 sup-
port the role of CK1 in phosphorylating hCTPS2 on Ser568 and
potentially other sites.
In summary, these studies provide novel enzymatic charac-
terization of the isolated hCTPS isoforms. Both hCTPS1 and
hCTPS2 are maximally activated at physiological concentra-
tions of ATP, GTP, and Gln, and both isoforms undergo tet-
ramerization in the presence of ATP and/or UTP. In addition,
both isoforms have a higher affinity for CTP compared with
UTP, suggesting that CTP feedback inhibition is important for
the regulation of hCTPS activity. Both isoforms also exhibit
increased phosphorylation after low serum treatment, suggest-
ing that hCTPS regulation is dependent on nutritional condi-
tions.Mutational analysis and deletion of the CRD supports the
hypothesis that phosphorylation of this peptide inhibits
enzyme activity. Whereas phosphorylation of Ser571 and Ser575
contributed significantly to hCTPS1 regulation, Ser568 was the
major phosphorylation site important for hCTPS2 regulation.
Thus the unique pattern of phosphorylation and phosphoryla-
tion by different kinases suggests that ultimately different
mechanisms of regulation control the activity of these individ-
ual isoforms.
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